Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.
J Clin Oncol · 2026-Jan-20 · PMID 41370738
OS
FIG 3. (A) Response rates, (B) MRD negativity rates, and (C) OS in the intention-to-treat population. a HR and corresponding 95% CI were determined by using stratified Cox proportional hazard model. b Includes two additional patients who had not yet been randomly assigned at the time of the primary analysis data cutoff date. CR, complete response; HR, hazard ratio; MRD, minimal residual disease; NE, not evaluable; ORR, overall response rate; OS, overall survival; PD, progressive disease; PomDex, pomalidomide and dexamethasone; PR, partial response; sCR, stringent complete response; VenDex, venetoclax and dexamethasone; VGPR, very good PR.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-23T17:02:33+00:00 |